articular steroid treatment and the patient soon began to decline joint aspiration and injection due to needle phobia. He was initially treated with NSAIDs, followed by methotrexate (first orally, subsequently subcutaneously). Due to inadequate disease control, adalimumab was added to subcutaneous methotrexate. His joint disease has, however, failed to respond to these treatments and has progressed to involve his contralateral knee as well as his right shoulder and elbow. In view of his disease progression, his biologic treatment was switched to intravenous tocilizumab at four-weekly intervals. Though he had initially demonstrated aclinical response to tocilizumab and methotrexate in combination, he developed gastrointestinal symptoms that required discontinuation of methotrexate. Following this, his disease activity increased further and control could not be regained in spite of escalation of the tocilizumab frequency to two-weekly dosing intervals. He has therefore been switched to intravenous abatacept, though he has not yet demonstrated any clinical or biochemical response. Unfortunately, throughout this time he has had significant systemic disease manifestations with weight loss, ongoing anaemia and a CRP that is commonly in excess of 100mg/dl. In order to establish a degree of control of his disease, he has been treated with oral prednisolone but has now had protracted steroid therapy with doses in excess of 10mg daily to maintain his function. Despite ongoing steroid treatment, he has rapid radiographic progression and significant functional disability. Early in 2018, the patient developed acutely worsening right shoulder pain and a large effusion.In view of hisimmunosuppression and systemic symptoms, we were concerned that he had developed a septic arthritis. The patient declined joint aspiration, even under ultrasound guidance and thus we have been unable to exclude this diagnosis and have had to elect to continue his immunosuppression and monitor his progress clinically and radiologically. Repeated imaging of this joint has shown ongoing erosive disease with extensive synovial thickening and effusion. The paient's treatment has been complicated by inconsistent compliance with drug therapies and blood monitoring, partly due to his needle phobia but also due to a complex social situation. He is a lone parent and works full-time in a fast food restaurant -responsibilities that he finds difficult to balance with attending blood monitoring, infusion and follow-up appointments. This has posed a challenge to the department as his unpredictable attendance has meant that doses of high-cost biologic drugs have been wasted on a number of occasions. Special arrangements are now in place, in that the patient must attend the day unit prior to his infusion being ordered and wait on the day; however, the time that this takes presents a further barrier to his attendance. These arrangements highlight that the patient is not yet afully independent, autonomous adult, in spite of being a parent himself. Furthermore, he does not seem to fully grasp the implications of his disease for hisfuture. Discussion: We present this case as the patient is now coming to the end of evidence-based, licensed and approved treatment pathways in JIA without adequate control of his disease. The next management options are uncertain, particularly in a general adult clinic with relatively small numbersof JIA patients and limited experience of this situation. This highlights the challenges faced when dealing with adults with persistent JIA, as the licensed treatment options are few and evidence-base sparse. In addition, this case highlights an important issue about managing young adults. A significant literature exists around the importance of transitional care in the adolescent population and the continuing unmet needs of this group. This literature eloquently describes the psychological and social barriers that JIA patients can face in young adulthood. This patient, however, presented directly to adult services and has therefore never experienced paediatric services or transition. Superficially, this would imply thathe shouldbe easier tomanage ashe does nothave the social andpsychological morbidity associated with a chronic disease in childhood. In spite of this, the challenges that he faces are demonstrably similar to post-transition young adults with JIA, indicating that planning and facilitating care for young adults goes beyond the provision of effective transition. Key Learning Points: In order to manage the patient's care effectively in future, close collaboration between paediatric and adult rheumatology services is required. Experiences of managing JIA across the continuum is clearly necessary in order to plan long-term treatment. Alongside case discussions, there is clearly a role for collaboratively planning data collection and research to provide longitudinal data for outcomes of persistent, active JIA in adults. In addition, the provision of care for young adults in rheumatology needs to look beyond the management of transition in order to address the need of young people presenting to both paediatric and adult services. We wish to start an open conversation about experiences of managing adolescent patients, both in terms of planning drug treatment and the practical, psychological and social support that other centres offer in order to facilitate this treatment. Disclosure: S. Brockbank: Other; SB has received funding from Pfizer and UCB for conference. J.Dawson: None.
Introduction: We report a case of a 15 year old girl with extended oligoarticular juvenile idiopathic arthritis (JIA) and chronic bilateral uveitis who had undergone a delayed adverse event to the infliximab biosimilar remsima, resulting in a tachyarrhythmia, significantly elevated troponin I and a diagnosis of transient acute coronary syndrome. This is the first reported case in the paediatric and adolescent population. Case description: Diagnosed at the age of 15 months with oligoarticular juvenileidiopathic arthritis, rapidly transforming to the extended subtype, her arthritis was eventually well controlled with methotrexate and NSAIDS. ANA was positive. On routine ophthalmological assessment asymptomatic uveitis was noticed. Over the years this has become bilateral, chronic and difficult to control despite regular courses of glucocorticoid eye drops and oral preparations. After secondary failure to adalimumab, infliximab 6mg/kg monthly was commenced in 2016, predominantly to achieve control of her uveitis. Initial response was promising and both eyes and joints remained quiet for 10 months. However, following cessation of oral steroids and reduction of steroidal eye drops, with remsima extended to six-weekly infusions, there was serious reactivation of bilateral uveitis. Four doses of remsima were administered fortnightly, followed by the monthly regimen. Topical and oral steroids were restarted. During a couple of these infusions, in early 2018, brief episodes of flushing, dyspnoea and chest tightness ensued but rapidly resolved on slowing down the infusion rate to six-hourly. Hydrocortisone and chlorphenamine were co-administered. Twenty-four hours following her last remsima infusion in May 2018, palpitations, followed by chest pains developed. This was associated with feeling clammy, sweating and breathless. Symptoms persisted for eight hours, which prompted an emergency admission. Heart rate was recorded as 203 beats per minutes. Blood pressure 108/56mmHg. Palpitations ceased just prior to obtaining an ECG and unfortunately the rhythm was not captured. ECG post-termination of palpitations was of normal sinus rhythm without ischaemic changes. Blood tests demonstrated a significantly elevated troponin I a t 1827ng/L (normal range <15.7ng/L). D-dimer 8422ug/L, CRP 4, lactate 0.9 and CK 153u/L. Electrolytes, bone profile, lipid profile, eosinophils and remaining blood tests were unremarkable. Viral screen was negative. Infliximab drug level was <0.3ug/mL and anti-infliximab antibodies <10ng/mL. There was no personal or family history of cardiac disease or arrhythmias. Differentials at this stage included a delayed drug reaction resulting in a tachyarrhythmia, myocarditis or a thromboembolic event. On further discussion with Great Ormond Street Hospital, the advice was to perform a CT pulmonary angiography. CT coronary angiogram and echocardiogram did not yield any sinister pathology. During the observation period, no further arrhythmias arose. Follow-up was arranged with a 48 hour tape. Repeat troponin had normalised within seven days. Remsima has since been discontinued and the patient is currently undergoing a washout period of 12 weeks before proceeding to the next linebiologic, tocilizumab. Discussion: Subjects who develop antibodies to infliximab are thought to be at a three-fold increased risk of developing infusion reactions. Side effects at the time of the infusion including: flushing, chest tightness, palpitation, dyspnoea, hypotension and even cardiopulmonary reactions have been documented by the manufacturers, however troponin rise and arrythmias in children are unheard of. For many, resolution of symptoms occurs on slowing down the infusion rate. Arrythmias and palpitations have been reported during infliximab and biosimilar infusions in the adult population in the region of 4-6%, however delayed cardiac reactions are less common and most adult patients are expected to have some form of underlying cardiovascular disease. There have only been three case reports of infliximab related acute coronary syndrome in adults. To our knowledge, this is the first documented case in the adolescent and paediatric cohort. Of the three case reports in the literature, one had cardiovascular risk factors, whilst the other two were both middle aged males, who had developed an acute coronary syndrome during the fifth infusion and three days after the infliximab infusion respectively. The latter had received long term non-steroidal anti-inflammatory drugs and corticosteroids. All three had ischaemic ECG changes. Despite the inability to capture the rhythm prior to its self-termination, a documented reading of a heart rate >200 beats per minute was strongly suggestive of a tachyarrhythmia, which would explain the symptoms experience by the patient. A significantly elevated troponin however, could not be explained by a tachyarrhythmia alone. One hypothesis for developing an acute coronary syndrome, is the vasodilatation role of TNF in the maintenance of myocardial vascular perfusion through the induction of nitric oxide. It is also capable of inhibiting apoptosis of myocardiocytes and attenuation of cardiac stimulation by the sympathetic nervous system through breceptors. The administration of Infliximab, which is a potent anti-TNF antibody can neutralise both soluble and membrane-bound TNF which can suspend these homeostatic mechanisms, resulting in deprivation of first line defences and leading to coronary vasoconstriction and hypoperfusion. Why patients without prior cardiovascular disease develop such symptoms isstill unclear and maybe a further scope for research. Key Learning Points: Potent anti-TNF agents have the theoretical ability of causing coronary vasoconstriction and hypoperfusion. Albeit rare, patients presenting with chest pain, during or after the infusion should have the appropriate coronary biochemistry and investigations performed. Young people with no risk of cardiovascular disease can develop transient acute coronary syndrome in response to potent anti-TNF agents. Doubling the frequency of infusion in attempt to regain control of disease after secondary failure should be done with caution and may increase the risk. Introduction: Behc¸et's disease (BD) is an idiopathic, multi system, autoinflammatory vasculopathic disorder, characterised by mouth and genital ulcers, rash, arthritis and uveitis. Ocular manifestations occur in up to 80% of patients and are associated with 30% risk of blindness. We present a challenging case of an adolescent with paediatric onset BD and aggressive refractory uveitismainly affecting the left eye. Case description: An 11 year old girl presented acutely with a three day history of a painful red left eye and blurred vision. Examination revealed bilateral uveitis with optic disc swelling, cystoid macular oedema (worse in left eye), 2 plus cells in her right eye, 3 plus cells in her left eye (according to standardisation of uveitis nomenclature classification) with snowballs and reduced visual acuity. A two-year history of mouth and genital ulcers wasgiven andatpresentationmild arthritiswas detected.Initialtreatment with intravenous methylprednisolone (IVMP), intensive topical steroid eye drops and subcutaneously administered methotrexate (15mg/m 2 ) was commenced. Infliximab (6 mg/Kg intravenously four-weekly) and mycophenolate mofetil (MMF, 600mg/m 2 orally twice-daily) were subsequently added for multi-focal chorioretinitis in the left temporal retina. Infliximab was changed to tocilizumab (8mg/Kg intravenously 2-weekly) in response to reduced vision as a result of persisting chronic cystoid macular oedema. Subsequently, tocilizumab was changed to adalimumab (40mg subcutaneously fortnightly), for repeated sight-threatening uveitis flare-ups. Fifteen months after initial presentation MMF and adalimumab were substituted for pulsed intravenous cyclophosphamide (initially 500mg/m 2 fortnightly, increasing to a maximum 1g/m 2 3-weekly; total 6 doses) for pseudo-hypopyon, recurrent widespread multi-focal chorioretinitis and acute sight loss (6/60).Multiple pulses of IVMP and oral prednisolone were given throughout the treatment course in response to repeated flare-ups of inflammation associated with reduced visual acuity due to macular oedema. Despite cyclophosphamide treatment, further severe flare-ups of eye disease complicated by pseudo-hypopyon, optic-disc swelling, multi-focal choroiditis and pseudo-necrotising retinitis occurred. Following cyclophosphamide, interferon-alfa-2A (roferon A, 3 million units subcutaneously daily) was commenced resulting in sustained and complete remission of eye inflammatory features including previously refractory cystic macular oedema; vision improved significantly to 6/9þ. Interferon-alfa-2A had been well tolerated and demonstrated clinical effectiveness from the first week. However, following further flares, the dose was increased to 6 million units subcutaneously daily. Ocular disease remained relatively stable for 6 months although the other BD manifestations, such as, mouth ulcers remained problematic. An acute episode occurred consisting of pseudo-hypopyon, panuveitis, multifocal choroiditis and exudative retinal detachment. During the course of the illness, two years and five months after presentation, the patient developed functional visual loss and was managed with psychology intervention. Eye inflammation improved significantly with pulsed IVMP, and continued to require IVMP.However, disease flares with recurrent skin rashes occurred. Recommendations were followed, from liaising closely with National Paediatric Behc¸et's Centre at Alder Hey Hospital. Methotrexate was discontinued, interferon-alfa-2A was discontinued and adalimumab 40mg started by weekly injection alongside azathioprine 50mg orally once daily, gradually increased to 125mg. Mouth and genital ulcers of BD have subsided although clinically the patient is now left with visual impairment in the left eye due to probable occlusive vasculitis related optic neuropathy. A well-planned and coordinated transition pathway is in process for this now adolescent patient. This involves a collaborative and iterative approach with both the adult uveitis team and the patient and family, to ensure that the psychological manifestations of this complex disease are addressed and well supported throughout the transition period and beyond. Throughout the treatment pathway we collaborated with colleagues in national centres of expertisefor paediatric BD and uveitis. Discussion: For this patient, it has been proven to be significantly challenging to achieve long lasting remission of the ocular manifestations in BD. However, the disease has always responded well to prompt interventions with pulsed IVMP. Key Learning Points: The challenges of treating Behc¸et's uveitis to achieve remission whilst preserving vision are well recognised. This case adds to the emerging evidence for the use of interferon-alfa-2A in treating Behc¸et's uveitis. The psychological impact of both the chronic diseases and treatment burden must be routinely assessed in the management of young people. A robust and well planned transition pathway is essential for adolescents with chronic complex disease processes such as Behc¸et's uveitis. Introduction: Takayasu arteritis is a chronic, granulomatous vasculitis of large vessels, involving the aorta and its major branches. Its aetiology is unknown and disease progression is variable with 10-year survival >90%. Takyasu arteritis is rare in children and young people (CYP). It is more frequent in Asian countries compared to Europe and North America, but the incidence is unknown. A 2010 review reported only 241 cases in CYP were reported worldwide. This case is of a 14 year old adolescent diagnosed with Takayasu arteritis six years ago aged eight. We outline the complex progression through his disease which has proved refractory to multiple treatments which themselves have caused morbidity. The case highlights many of the biomedical as well as psychosocial issues that can challenge teams looking after children and young people with rare conditions and the particular complexities that adolescence adds. Case description: The patient was born in 2004 and grew up as part of a travelling family living on a static site. He had no health or developmental problems until 2012 when he presented with fatigue, weight loss, back pain, swollen ankles, and daily fever. At the time of presentation he had no arthritis, no skin rash, and no neurological signs. His left brachial pulse was diminished and right dorsalis pedis was absent (clinically and by USS). His left carotid pulse was present, but the right diminished (by USS). There was a difference of 20mmHg in systolic blood pressure in his arms (elevated on the right). His ESR was 108. A CT chest showed a widened mediastinum and renal USS showed stenosis of both renal arteries, more on the left side. An MRA showed diffuse thickening to the walls of both common carotids and proximal internal carotid bilaterally with 50% stenosis of the right internal carotid artery. Based on these findings, he was diagnosed with Takayasu arteritis. The patient was started on treatment with corticosteroids (initially intravenous later orally), intravenous cyclophosphamide and subcutaneous methotrexate. He was commenced on low molecular weight heparin (LMWH) with a plan to switch to
